Stock Price
1,020.44
Daily Change
-86.68 -7.83%
Monthly
-4.10%
Yearly
17.24%
Q1 Forecast
1,005.21

Eli Lilly reported $40.87B in Loan Capital for its fiscal quarter ending in September of 2025.





Loan Capital Change Date
AbbVie USD 62.97B 12M Sep/2025
Abbott USD 11.6B 1.33B Sep/2025
ALKERMES USD 285.82M 639K Sep/2024
Amgen USD 52.43B 1.33B Sep/2025
AstraZeneca USD 6.55B 19.43B Sep/2025
Baxter International USD 9.49B 80M Jun/2025
Biogen USD 6.29B 1.4M Sep/2025
Bristol-Myers Squibb USD 44.47B 1000K Sep/2025
Drreddys Laboratories INR 129.19M 1.84M Dec/2025
Eli Lilly USD 40.87B 6.69B Sep/2025
Gilead Sciences USD 22.14B 5M Sep/2025
GlaxoSmithKline GBP 14.71B 186M Dec/2025
Glaxosmithkline GBP 20.02B 4.72B Sep/2025
J&J USD 39.41B 173M Sep/2025
Medtronic USD 26.18B 537M Jun/2025
Merck USD 39.97B 6B Sep/2025
Neurocrine Biosciences USD 169.5M 500K Mar/2023
Novartis USD 24.24B 174M Sep/2025
Novartis USD 24.24B 174M Sep/2025
Novo Nordisk DKK 118.94B 29.76B Dec/2025
Perrigo USD 3.61B 7.4M Sep/2025
Pfizer USD 57.41B 93M Sep/2025
Prestige Brands USD 1.05B 39.73M Dec/2025
Regeneron Pharmaceuticals USD 2.71B 720.4M Dec/2025
Roche Holding CHF 27.43B 966M Dec/2025
Sanofi EUR 15.72B 2.45B Dec/2025
Sanofi EUR 15.72B 150.06M Dec/2025
United Therapeutics USD 100M 100M Jun/2024
Zoetis USD 7.07B 1.84B Sep/2025